NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Alcobra Ltd. (NASDAQ:ADHD) (“Alcobra”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

Pre-market on January 17, 2017, Alcobra revealed that Metadoxine Extended Release, its attention deficit hyperactivity disorder drug, failed to meet its primary endpoint in its Phase 3 trial. On this news, Alcobra stock dropped over 50% to close at $0.94 January 17, 2017. To obtain additional information, go to:

http://zlk.9nl.com/Alcobra_ADHD

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170118006205/en/